drugset / Trial / NCT04510649
Surufatinib DDI With a PPI and a CYP3A Inducer
Non-randomizedCrossoverOpen-labelBasic science
Summary
The purpose of this is to evaluate the effect of proton pump inhibitor (rabeprazole) and the effect of a CYP3A inducer (rifampin) on the pharmacokinetics of Surufatinib.
Timeline
- Start
- 2020-07-09
- Primary completion
- 2020-09-11
- Completion
- 2021-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | — |
| Background | Rabeprazole | Small molecule | 30 mg | — |
| Background | Rifampin | Small molecule | 600 mg | — |
Indications
No indication recorded.